Sponsors (15)
The bill directs targeted federal funding, data-sharing rules, and programs to accelerate brain tumor research, clinical-trial access, and survivorship care—potentially improving outcomes and equity for patients—while increasing federal costs, adding administrative and privacy risks, and risking diversion of research resources from other priorities.
People with brain tumors (adult and pediatric) stand to gain faster development and earlier access to new treatments because the bill directs new, targeted research funding and programs for brain tumor and glioblastoma therapies, including pediatric inclusion.
Patients and clinicians will have improved access to clinical-trial information and broader enrollment opportunities as the bill funds outreach/education, trial navigation resources, and guidance to design more inclusive eligibility criteria.
Brain tumor survivors and their families will receive better follow-up care and psychosocial supports through pilot programs, multidisciplinary care models, peer mentoring, and tools for transition-to-post-treatment care.
Taxpayers will face increased federal spending (notably ~$60M/year for immunotherapy plus additional authorizations), which could add to deficits or require shifting funds from other priorities.
Research institutions and biorepository holders will incur administrative burdens to comply with new biospecimen reporting requirements and program rules, diverting staff time and resources from research or clinical care.
Focused appropriations for glioblastoma and related programs risk diverting NIH and other federal research resources away from other diseases or investigator-initiated priorities.
Based on analysis of 12 sections of legislative text.
Directs NIH to create a public biospecimen registry, funds glioblastoma and cellular immunotherapy research, supports survivor-care pilots, runs an outreach campaign, and tasks FDA with guidance.
Introduced April 8, 2025 by Richard Blumenthal · Last progress April 8, 2025
Strengthens federal support for brain tumor research, clinical development, patient outreach, and survivorship care. It requires NIH to publish a searchable public inventory of NIH-funded brain tumor biospecimens, creates new multi-institutional research programs for glioblastoma and cellular immunotherapies with multi-year funding authorizations, funds demonstration projects and an outreach campaign to raise awareness about cancer clinical trials and biomarker testing, and directs FDA to issue guidance to reduce unnecessary exclusion of brain tumor patients from clinical trials for other indications.